Last Updated on 2026 年 3 月 24 日 by 総合編集組
Advances in Precision Medicine for Colorectal Cancer (2024-2026): From Molecular Targets to Clinical Applications in Taiwan and Beyond
Introduction Colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths worldwide, with over 1.9 million new cases and approximately 900,000 deaths annually as estimated in 2026. In Taiwan, it consistently ranks as the most common cancer, with around 22,000 new diagnoses and 7,000 deaths each year. While early-stage (stages I-II) five-year relative survival reaches 90%, metastatic colorectal cancer (mCRC) poses significant challenges, affecting about 20% of patients at initial diagnosis and another 50% after local recurrence.
Over the past decade, treatment has shifted from a one-size-fits-all chemotherapy approach to biomarker-driven precision medicine. Comprehensive genomic profiling—including RAS (KRAS/NRAS), BRAF V600E, microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR), HER2 amplification, and NTRK fusions—has become essential before initiating systemic therapy. This article summarizes key advancements from 2024 to 2026, focusing on pivotal trials, regulatory approvals, Taiwan’s health insurance updates, and supportive strategies. (Word count so far: ~180)
BRAF V600E-Mutated Metastatic CRC: Transforming First-Line Treatment with Triplet Targeted Therapy BRAF V600E mutation occurs in approximately 10% of mCRC cases and is associated with aggressive disease and poor prognosis, with historical median overall survival (OS) often below 15 months due to resistance to conventional chemotherapy. The breakthrough came with encorafenib (Braftovi) combined with cetuximab (Erbitux) and fluorouracil-based chemotherapy (such as mFOLFOX6 or FOLFIRI).
On February 24, 2026, the U.S. FDA granted traditional approval for this regimen in adult patients with BRAF V600E-mutated mCRC, based on the phase 3 BREAKWATER trial (NCT04607421). In the triplet arm (encorafenib + cetuximab + mFOLFOX6), median OS reached 30.3 months compared to 15.1 months in the control arm (standard chemotherapy ± bevacizumab), representing a 51% reduction in death risk (HR = 0.49; P < 0.0001). Progression-free survival (PFS) and objective response rate (ORR) also showed statistically significant improvements.
The scientific rationale involves blocking MAPK pathway feedback activation: BRAF inhibition alone can lead to EGFR compensatory signaling, necessitating concurrent anti-EGFR antibody use. In Taiwan, the National Health Insurance Administration (NHIA) began reimbursing encorafenib plus cetuximab for BRAF V600E patients as second-line therapy from March 1, 2026, benefiting an estimated 1,548 patients annually. This policy also removed fixed prescription restrictions for cetuximab and panitumumab under certain conditions, aligning Taiwanese practice more closely with international first-line standards.
Real-world patient experiences shared on forums highlight dramatic responses, such as complete disappearance of liver and lymph node metastases after three months, or achievement of no evidence of disease (NED) status even in severely debilitated cases. However, side effects like oxaliplatin-induced peripheral neuropathy and cetuximab-related acneiform rash require proactive management with moisturizers, doxycycline prophylaxis, and resistance training. (Word count so far: ~520)
Immunotherapy Revolution for MSI-H/dMMR Subgroup MSI-H or dMMR tumors account for about 4% of mCRC cases. These tumors respond poorly to chemotherapy but are highly sensitive to immune checkpoint inhibitors. On January 14, 2026, Taiwan’s TFDA approved nivolumab (Opdivo) plus ipilimumab (Yervoy) for first-line treatment of MSI-H/dMMR mCRC, based on the phase 3 CheckMate 8HW trial.
The dual immunotherapy arm achieved an ORR of 72.0% versus 38.0% with chemotherapy, with two-year PFS exceeding 65% compared to below 30% in the control group. By simultaneously blocking PD-1 and CTLA-4 pathways, the combination generates a more robust and durable antitumor immune response. Immune-related adverse events need close monitoring, but overall tolerability is better than chemotherapy’s hematologic toxicity and nausea.
The impact extends to early-stage disease. The ATOMIC trial added atezolizumab (a PD-L1 inhibitor) to standard adjuvant mFOLFOX6 in stage III dMMR colon cancer, improving three-year disease-free survival from 76.6% to 86.4%. This supports expanding immunotherapy into high-risk adjuvant settings. (Word count so far: ~720)
HER2-Positive Colorectal Cancer: Antibody-Drug Conjugates Open New Frontiers HER2 amplification occurs in 3-5% of CRC cases and serves as a key rescue target when anti-EGFR therapies fail. Trastuzumab deruxtecan (T-DXd, Enhertu), a novel antibody-drug conjugate (ADC), leads this field.
The DESTINY-CRC02 phase 2 trial evaluated T-DXd in heavily pretreated HER2-positive mCRC patients. At 5.4 mg/kg, the confirmed ORR was 37.8% with median OS of 15.9 months and interstitial lung disease (ILD) rate of 9.6% (mostly low-grade). The 6.4 mg/kg dose showed numerically higher OS (19.7 months) but increased toxicity (ILD 17.9%). Thus, 5.4 mg/kg is recommended as the standard dose for balancing efficacy and safety.
T-DXd’s high drug-to-antibody ratio and bystander effect allow it to kill neighboring cancer cells even in heterogeneous HER2 expression tumors. Additional HER2-directed ADCs like JSKN003 are now in phase 3 trials (JSKN003-005) comparing against regorafenib or fruquintinib, promising further options. (Word count so far: ~920)
KRAS Mutations: From “Undruggable” to Precision Inhibition RAS mutations (40-50% of CRC) were historically linked to poor prognosis and limited targeted options. Recent inhibitors are changing this narrative.
For KRAS G12C (present in ~3% of mCRC), the next-generation covalent inhibitor MK-1084 demonstrated 38% ORR as monotherapy and 46-50% when combined with cetuximab in the KANDLELIT-001 study. The ongoing phase 3 KANDLELIT-012 trial evaluates MK-1084 + cetuximab + mFOLFOX6 in the first-line setting.
For the more common KRAS G12D mutation, zoldonrasib (RMC-9805) received FDA Breakthrough Therapy Designation on January 8, 2026. Early NSCLC data showed 61% ORR, with expansion now underway in MSS-type G12D-mutated CRC. These developments mark a significant shift toward actionable KRAS targeting. (Word count so far: ~1,080)
Later-Line Therapy: Fruquintinib as a Cornerstone For patients who have progressed after chemotherapy, anti-VEGF, and anti-EGFR agents, fruquintinib (Fruzaqla)—a highly selective VEGFR 1/2/3 tyrosine kinase inhibitor—offers meaningful benefit.
The international phase 3 FRESCO-2 trial showed median OS of 7.4 months versus 4.8 months with placebo plus best supportive care (HR 0.66, 34% risk reduction). Disease control rate reached 55.5% versus 16.1%, despite a low ORR of 1.5%. The value lies in stabilizing disease in over half of heavily pretreated patients.
Patient-reported experiences describe challenges such as hypertension, tachycardia, voice changes, severe gas pain, and occasional renal/hepatic toxicity—often managed as an ongoing “whack-a-mole” process with supportive medications and monitoring. Nevertheless, many view it as a bridge to newer therapies. (Word count so far: ~1,280)
Liquid Biopsy and Minimal Residual Disease (MRD) Monitoring Circulating tumor DNA (ctDNA) testing has moved into routine clinical use for non-invasive, dynamic monitoring. Data from the 2025 AACR meeting indicated that ctDNA can detect recurrence with a median lead time of 198 days—about six months earlier than conventional CT imaging. This window enables earlier intervention, as explored in trials like DYNAMIC-III.
ctDNA also tracks acquired resistance to anti-EGFR therapies by detecting emerging RAS mutations and supports “re-challenge” strategies when resistant clones disappear after treatment interruption. (Word count so far: ~1,380)
Supportive Care Updates: Exercise, Diet, and Lifestyle Integration The 2026 ESMO guidelines for localized colon cancer formally incorporate structured physical activity. A large international study of nearly 900 stage II-III patients found that participation in exercise programs reduced the risk of cancer recurrence or new primaries by 28%. Resistance training is particularly important for preserving muscle mass and bone density during treatment.
Dietary patterns matter too: high intake of pro-inflammatory foods (processed meats, refined carbohydrates, sugary drinks) correlates with worse survival in stage III disease. Combining anti-inflammatory eating with regular exercise yields the greatest overall survival benefit. (Word count so far: ~1,520)
2026 Treatment Landscape in Taiwan and Future Outlook In Taiwan, the March 2026 NHIA reimbursement expansion for BRAF-targeted therapy represents a milestone toward global alignment. First-line options now emphasize triplet targeted therapy for BRAF V600E (pushing median OS toward 30 months) and dual immunotherapy for MSI-H/dMMR. Emerging KRAS inhibitors and HER2 ADCs expand choices for previously difficult-to-treat genotypes, while fruquintinib and optimized later-line combinations strengthen refractory disease management. ctDNA-guided MRD monitoring promotes personalized adjuvant de-escalation or intensification, reducing overtreatment.
With comprehensive genomic testing, multidisciplinary team (MDT) collaboration, and integration of healthy lifestyle measures, metastatic CRC is increasingly viewed as a manageable chronic condition rather than an immediately terminal diagnosis. Ongoing research continues to refine molecular subtyping and combination strategies. (Word count so far: ~1,720)
Conclusion Precision medicine has fundamentally reshaped colorectal cancer care between 2024 and 2026. By matching therapies to specific molecular drivers—BRAF, MSI-H/dMMR, HER2, and now KRAS—clinicians can deliver more effective and less toxic regimens. Taiwan’s policy adjustments further improve access. Patients and families should discuss biomarker testing and individualized plans with their oncology teams. While these advances bring hope, treatment decisions must always prioritize professional medical advice, considering each person’s unique clinical situation, comorbidities, and preferences. Continued research, real-world evidence collection, and supportive care optimization will further enhance quality of life and long-term outcomes.
Important Disclaimer: This summary is for informational purposes only, based on publicly available trial data and regulatory information as of early 2026. It does not constitute medical advice, diagnosis, or treatment recommendation. Always consult qualified healthcare professionals. No investment advice is provided, and no guarantees are made regarding efficacy or outcomes for any individual.
